129 related articles for article (PubMed ID: 11855679)
21. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H; Yano I; Saito H; Inui K
Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
23. New quinolone, grepafloxacin, inhibits Cl- secretion across bovine airway epithelium in culture.
Kanoh S; Tamaoki J; Kondo M; Nagai A
Respirology; 2001 Mar; 6(1):51-6. PubMed ID: 11264763
[TBL] [Abstract][Full Text] [Related]
24. The clinical pharmacokinetics of levofloxacin.
Fish DN; Chow AT
Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
[TBL] [Abstract][Full Text] [Related]
25. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
Chow AT; Fowler C; Williams RR; Morgan N; Kaminski S; Natarajan J
Antimicrob Agents Chemother; 2001 Jul; 45(7):2122-5. PubMed ID: 11408234
[TBL] [Abstract][Full Text] [Related]
26. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat.
Sasabe H; Terasaki T; Tsuji A; Sugiyama Y
J Pharmacol Exp Ther; 1997 Jul; 282(1):162-71. PubMed ID: 9223551
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions.
Kikuchi E; Kikuchi J; Nasuhara Y; Oizumi S; Ishizaka A; Nishimura M
Antimicrob Agents Chemother; 2009 Jul; 53(7):2799-803. PubMed ID: 19380601
[TBL] [Abstract][Full Text] [Related]
28. Effect of bile duct ligation and unilateral nephrectomy on brain concentration and convulsant potential of the quinolone antibacterial agent levofloxacin in rats.
Akahane K; Ohkawara S; Nomura M; Kato M
Fundam Appl Toxicol; 1996 Feb; 29(2):280-6. PubMed ID: 8742326
[TBL] [Abstract][Full Text] [Related]
29. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy.
Andrews JM; Honeybourne D; Jevons G; Brenwald NP; Cunningham B; Wise R
J Antimicrob Chemother; 1997 Oct; 40(4):573-7. PubMed ID: 9372428
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of grepafloxacin.
Efthymiopoulos C
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
[TBL] [Abstract][Full Text] [Related]
31. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
32. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
Zhao YL; Cai SH; Wang L; Kitaichi K; Tatsumi Y; Nadai M; Yoshizumi H; Takagi K; Takagi K; Hasegawa T
Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):167-72. PubMed ID: 11906478
[TBL] [Abstract][Full Text] [Related]
33. Tissue pharmacokinetics of levofloxacin in human soft tissue infections.
Bellmann R; Kuchling G; Dehghanyar P; Zeitlinger M; Minar E; Mayer BX; Müller M; Joukhadar C
Br J Clin Pharmacol; 2004 May; 57(5):563-8. PubMed ID: 15089808
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells.
Hirano T; Yasuda S; Osaka Y; Kobayashi M; Itagaki S; Iseki K
Biochim Biophys Acta; 2006 Nov; 1758(11):1743-50. PubMed ID: 16928358
[TBL] [Abstract][Full Text] [Related]
35. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat.
Sasabe H; Kato Y; Tsuji A; Sugiyama Y
J Pharmacol Exp Ther; 1998 Feb; 284(2):661-8. PubMed ID: 9454812
[TBL] [Abstract][Full Text] [Related]
36. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
37. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes.
Tachibana M; Tanaka M; Masubuchi Y; Horie T
Drug Metab Dispos; 2005 Jun; 33(6):803-11. PubMed ID: 15769885
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery.
Gascón AR; Campo E; Hernández RM; Calvo B; Errasti J; Pedraz Muñoz JL
J Clin Pharmacol; 2000 Aug; 40(8):869-74. PubMed ID: 10934671
[TBL] [Abstract][Full Text] [Related]
39. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics and distribution of ofloxacin into the lower respiratory tract.
Walstad RA; Vilsvik JS; Thurmann-Nielsen E; Rolstad T
Drugs; 1995; 49 Suppl 2():344-5. PubMed ID: 8549356
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
